Shell Plc 1st Quarter 2025 Unaudited Results - Shell ( NYSE:SHEL )
Income attributable to Shell plc shareholders, compared with the fourth quarter 2024, reflected lower exploration well write-offs, lower operating expenses and higher Products margins.
Shell plc First Quarter 2025 Interim Dividend
London, May 2, 2025 − The Board of Shell plc ( the "Company" ) ( XLON: SHEL, XNYS: SHEL, XAMS: SHELL ) today announced an interim dividend in respect of the first quarter of 2025 of US$ 0.358 per ordinary share.
Increase of Share Capital in Connection with the Exercise of the Options Programme and Subscription Results
The Supervisory Board of AS LHV Group has decided to increase the share capital of the LHV Group by EUR 366,721.30. The increase was triggered by the need to issue new shares to staff members participating in the share options programme approved by the resolution of the general meeting on 13 ...
Schouw & Co. to initiate share buy-back programme of up to DKK 120 million
The Board of Directors of Aktieselskabet Schouw & Co. has decided to initiate a share buy-back programme of up to DKK 120 million to be executed during the period 5 May to 31 December 2025.
Oil major Shell launches $3.5 billion share buyback after first-quarter profit beat
Shell's earnings come as Big Oil's profits continue to fall from record highs in 2022.
Meriaura Group Plc's business review for January-March 2025
Meriaura Group PlcBusiness review, insider information 2 May 2025 at 8.30 am ( CEST ...
Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom
COPENHAGEN, Denmark, May 2, 2025 - Bavarian Nordic A/S ( OMX: BAVA ) announced today that the UK Medicines and Healthcare products Regulatory Agency ( MHRA ) has granted marketing authorization in the United Kingdom ( UK ) for VIMKUNYA® ( recombinant, adsorbed ) for active immunization for the ...
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025
Tokyo, Japan and Cambridge, UK, 2 May 2025 - Nxera Pharma ( "the Company" or "Nxera". TSE: 4565 ) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2025. The full report can be found here.
Sui Gaming Stablecoin Launching for SuiPlay0X1 Handheld, Playtron Ecosystem
Playtron is gearing up to launch a Sui stablecoin custom-built for gaming in its handheld ecosystem, including the SuiPlay0X1.















